Therefore, we speculate that in future clinical treatments for cervical cancer, the use of antibodies or inhibitors targeting CLPTM1L could potentially improve the efficacy of cisplatin in treating advanced or recurrent cervical cancer. Here, CLPTM1L is linked to cervical cancer.